文献速递心血管MR

肥厚型心肌病患者左心房肌病与肌节突变的相关性:基于MRI特征追踪左心房应变的研究

Association between left atrial myopathy and sarcomere mutation in patients with hypertrophic cardiomyopathy: insights into left atrial strain by MRI feature tracking.
PubMed 文献 · Eur Radiol · 2023-08-28

回顾性纳入105例连续肥厚型心肌病患者,均行基因筛查和心脏MRI,评估左心房体积、射血分数及三相应变。突变阳性患者左心房最大体积指数更高、储器期和泵功能期应变更低,而管道期应变无差异;左心房泵功能期应变与肌节突变独立相关,且在Mayo II评分基础上提高突变预测效能。

要点

  • 肥厚型心肌病突变阳性患者左心房储器期和泵功能期应变降低,管道期应变无差异。
  • 左心房泵功能期应变与肌节突变独立相关(OR=0.86,95%CI 0.77-0.96,p=0.010)。
  • 左心房泵功能期应变在Mayo II评分基础上提高突变预测效能(AUC 0.798 vs 0.709,p=0.024)。

核心结论

  • 在肥厚型心肌病中,突变阳性患者左心房扩大更明显、储器期和泵功能期功能更差;左心房泵功能期应变是肌节突变预测的强因子,在Mayo II评分基础上具有增量价值。

研究设计与样本

  • 回顾性纳入105例连续肥厚型心肌病患者(平均年龄47.8±11.9岁,71%男性),均行肥厚型心肌病相关基因筛查和心脏MRI;分别评估左心房体积、射血分数及储器期、管道期、泵功能期应变指标。

关键影像表现/征象

  • 突变阳性患者左心房最大体积指数高于突变阴性患者(59.4±28.2 vs 43.8±18.1 mL/m2,p=0.001)。
  • 突变阳性患者左心房储器期应变低于突变阴性患者(21.3±7.9 vs 26.2±6.6%,p<0.001)。
  • 突变阳性患者左心房泵功能期应变低于突变阴性患者(12.1±5.4 vs 17.1±5.0%,p<0.001)。
  • 突变阳性与突变阴性患者左心房管道期应变无显著差异(9.2±4.5 vs 9.1±4.5%,p=0.909)。

诊断标准与关键数值

  • 多因素logistic回归中,左心房泵功能期应变与肌节突变相关(OR=0.86,95%CI 0.77-0.96,p=0.010),独立于最大室壁厚度、晚期钆增强和左心房体积。
  • 左心房泵功能期应变加入Mayo II评分后,突变预测AUC为0.798,单独Mayo II评分为0.709(p=0.024)。

临床应用与阅片要点

  • MRI特征追踪测量的左心房泵功能期应变可用于肥厚型心肌病患者肌节突变的预测,并在Mayo II评分基础上提供增量价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Left atrial (LA) myopathy, characterized by LA enlargement and mechanical dysfunction, is associated with worse prognosis in hypertrophic cardiomyopathy (HCM) while the impact of sarcomere mutation on LA myopathy remains unclear. We aimed to assess the association between LA myopathy and sarcomere mutation and to explore the incremental utility of LA strain in mutation prediction.

METHODS: A total of 105 consecutive HCM patients (mean age 47.8 ± 11.9 years, 71% male) who underwent HCM-related gene screening and cardiac MRI were retrospectively enrolled. LA volume, ejection fraction and strain indices in reservoir, conduit, and booster-pump phases were investigated respectively.

RESULTS: Fifty mutation-positive patients showed higher LA maximal volume index (59.4 ± 28.2 vs 43.8 ± 18.1 mL/m2, p = 0.001), lower reservoir (21.3 ± 7.9 vs 26.2 ± 6.6%, p < 0.001), and booster-pump strain (12.1 ± 5.4 vs 17.1 ± 5.0%, p < 0.001) but similar conduit strain (9.2 ± 4.5 vs 9.1 ± 4.5%, p = 0.909) compared with mutation-negative patients. In multivariate logistic regression, LA booster-pump strain was associated with sarcomere mutation (odds ratio = 0.86, 95% confidence interval: 0.77-0.96, p = 0.010) independent of maximal wall thickness, late gadolinium enhancement, and LA volume. Furthermore, LA booster-pump strain showed incremental value for mutation prediction added to Mayo II score (AUC 0.798 vs 0.709, p = 0.024).

CONCLUSIONS: In HCM, mutation-positive patients suffered worse LA enlargement and worse reservoir and booster-pump functions. LA booster-pump strain was a strong factor for sarcomere mutation prediction added to Mayo II score.

CLINICAL RELEVANCE STATEMENT: The independent association between sarcomere mutation and left atrial mechanical dysfunction provide new insights into the pathogenesis of atrial myopathy and is helpful to understand the adverse prognosis regarding atrial fibrillation and stroke in mutation-positive patients.

KEY POINTS: • In patients with hypertrophic cardiomyopathy, left atrial (LA) reservoir and booster-pump function, but not conduit function, were significantly impaired in mutation-positive patients compared with mutation-negative patients. • LA booster-pump strain measured by MRI-derived feature tracking is feasible to predict sarcomere mutation with high incremental value added to Mayo II score.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wang J, Ma X, Zhao K, et al. Association between left atrial myopathy and sarcomere mutation in patients with hypertrophic cardiomyopathy: insights into left atrial strain by MRI feature tracking. Eur Radiol. 2023. PMID: 37635167. doi:10.1007/s00330-023-10128-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。